This includes elevated natriuretic peptide levels,specifically BNP ≥300 ng/L or NT-proBNP ≥1000 ng/L in sinus rhythm,and BNP ≥500 ng/L or NT-proBNP ≥1600 ng/L in atrial fibrillation.However, the efficacy of vericiguat is reduced in patients with very highbaseline NT-proBNP levels, particularly those above 8000 pg/mL, as observed inthe subgroup analysis of the VICTORIA trial. Here, NPPB is linked to atrial fibrillation.